HFC-134a와 대체냉매 HFC-152a에 CF_3I를 혼합한 자동차냉매 특성

권일욱,박찬수,홍경한,문기선,최운수,서의경,윤갑식,이종인,하옥남 朝鮮大學校 機械技術硏究所 2002 機械技術硏究 Vol.5 No.1

These days, an attention of environment has been increasing all over the world. to prevent the green house effect and destruction of an ozone layer, an ozone destruction potential(ODP) be zero and a refrigerant for low global warming potential(GWP) is needed. HFC-134a, in which hydrogen is mixed instead of chlorine is a refrigerant used for automobile conditioners and its destruction potential is ecologically zero. However, it is not considered as a perfect substitutive refrigerant as its GWP is high. It is studied refrigerant mixtures in which HFC-134a, HFC-152a and CF_3I with low GWP and zero ODP are mixed by experimentally and concluded as follows; 1. with the variation of speed of compressor outside temperature and flow rate, the heat of evaporator and compressor and coefficient of performance was varied, and influenced the air conditioner. 2. The pressure of evaporator was decreased with increasing the speed of compressor and that of the refrigerant HFC-134a was higher 21% than that of azotrope refrigerant mixed with CF_3I. The overall capacity of condensor and evaporator was increased and HGC-134a was higher than azotrope refrigerant mixed with CF_3I 3. The capacity of evaporator with the refrigerant HFC-134a was higher 6% than azotrope refrigerant mixed with CF31 and the required power with zaotrope refrigerant mixed with CF_3I was higher 11% than that of HFC-134a. 4. The COP of the refrigerant FHC-134a was higher 31% in 1000RPM. when outside temperature was increased, COP was decreased. 5. Performance of HFC-134a is better than azotrope refrigerant mixed with CF_3I but prefered zaotrope refrigerant mixed with CF_3I considering the environment.

폐경기 여성에서의 Cyclofenil의 효능에 관한 연구 : 갱년기 장애 및 Ca 장흡수에 관하여

노흥규,윤상임,성기양,이경숙,이강욱 충남대학교 의과대학 지역사회의학연구소 1991 충남의대잡지 Vol.18 No.1

In postmenopausal syndrome, most common symptoms are those of vasomotor irritability such as hot flush and palpitation, irritable bladder symptoms and dyspareunia according to atrophy of urogenital epithelium, anxiety, nervousness, depression and insomnia. Approximately 40 percent of women in postmenopausal period develop symptoms serious enough to seek medical assistance. Among non-steroid agents, cyclofenil(4, 4' cyclohexidene methlyene diphenoacetate) is known to be a quite interesting substance according to the action at the level of the hypophyseal and hypothalamic centers by reducing the incretion of FSH and restoring normal endorphin, dopamine and norepinephrine activities, thus favorably affecting the whole postmenpausal neurovegutative symptomatology. In order to evaluate effect of cyclofenil on postmenopausal symptomatology and calcium metabolism, we examined 32 patients with postmenopausal syndrome before and after 200mg/day of oral cyclofenil treatment for 30-60 days. The results were as follows: 1. With 30 days of cyclofenil administration, subjective symptoms such as facial flush, palpitation, anxiety, nervousness and dyspareunia were improved significantly (p<0.001, p<0.001, p<0.01, p<0.005, respectively). But insomnia and depression were improved significantly after 60 days of cyclofenil administration (p<0.05, p<0.001, respectively). 2. Intestinal calcium absorption rate disclosed tendency of improvement without statistical significance 30 days after cyclofenil treatment. 3. Serum calcium and phosphorus level were not changed significantly before and after cyclofenil. 4. There was no definite evidence of side effects such as uterine bleeding due to cyclofenil. In conclusion, we thought that cycofenil is effective in management of postmenopausal syndrome but for the effect on calcium metabolism, further evaluation should be needed.

Role of bone marrow derived stem cells in endometrial regeneration

( Kyong Wook Yi ) 대한산부인과학회 2018 서울심포지움 Vol.23 No.-

Benign metastasizing Leiomyoma in the retroperitoneal space: Case report of 2 cases

( Kyong Wook Yi ),( Jong Ha Hwang ),( Hyun Jun Ji ),( Jung Ho Shim ),( Jun Young Hur ),( Ho Suk Saw ),( Yong Kyun Park ),( Jae Kwan Lee ) 대한산부인과학회 2007 대한산부인과학회 학술대회 Vol.93 No.-

The role of estrogen receptors alpha and beta in regulating adipokines expression in 3T3-L1 adipocytes

이경욱 ( Kyong Wook Yi ),( Jung Ho Shin ),( Min Jung Oh ),( Jae Kwan Lee ),( Tak Kim ),( Ho Suk Saw ),( Sun Haeng Kim ),( Jun Young Hur ) 대한산부인과학회 2007 대한산부인과학회 학술대회 Vol.93 No.-

경피 에스트로겐의 효과와 안전성

이경욱 ( Kyong Wook Yi ) 대한폐경학회 2009 대한폐경학회지 Vol.15 No.3

Hormone therapy (HT) has been used for many years to treat menopausal symptoms that are related to estrogen deficiency; hot flushes, night sweats, genital atrophy, and bone loss (osteopenia and osteoporosis). Over the last few years, the number of possible HT options has increased, and transdermal delivery systems, such as gels, patches, and creams, have also been developed. Percutaneous administration of estrogen circumvents the hepatic first-pass metabolism, and so this avoids the fluctuations in plasma hormone levels and it permits the use of lower doses of estradiol. Clinically, the transdermal route for administering estradiol is comparable to the presently existing therapies to treat menopause symptoms, and the transdermal route may have additional benefits on the cardiovascular system due to the beneficial effect on the plasma triglyceride, the glucose and insulin metabolism. Postmenopausal women with intolerance to the oral route are primarily indicated for transdermal estrogen therapy. The women with hypertriglyceridemia, those at a high risk for or who have had previous cholelithiasis, and those with persistent or recurring symptoms due to fluctuating levels of plasma estradiol should also be considered for transdermal estrogen therapy. (J Korean Soc Menopause 2009;15:135-144)

100 g 경구 당내성 검사상 내당능 장애를 보인 산모군의 주산기 결과

이경욱 ( Kyong Wook Yi ),정재원 ( Jae Won Jung ),신정호 ( Jung Ho Shin ),오민정 ( Min Jeong Oh ),이재관 ( Jae Kwan Lee ),허준용 ( Jun Young Hur ),서호석 ( Ho Suk Saw ),박용균 ( Yong Kyun Park ) 대한주산의학회 2006 大韓周産醫學會雜誌 Vol.17 No.1

목적 : 100 g 경구 당내성 검사에서 내당능 장애(impaired glucose tolerance)를 보인 산모들의 주산기 결과를 정상대조군 및 임신성 당뇨군과 비교하고자 하였다. 방법 : 2002년 3월부터 2004년 3월까지 본원 산부인과로 내원한 산모 중 50 g 당부하 검사에서 양성(≥140 mg)으로 나온 산모 159명을 대상으로 하였다. 100 g 경구 당내성 검사 결과 한개의 수치가 기준값보다 증가되어 있는 경우를 내당능 장애로 정의하였고 이들의 주산기 결과를 모든 결과가 기준이하인 정상대조군 및 임신성 당뇨군(2개 이상이 증가)과 비교하였다. 당뇨의 가족력, 이전 임신에서의 임신성 당뇨여부, 임신전 체질량지수(body mass index(BMI))를 비교하였으며 신생아 예후로는 출생시 90백분위수 이상의 과체중아및 4kg 이상의 거대아, 조기양막파수, 아프가 점수, 신생아 중환자실 입원일수, 저혈당증, 고빌리루빈혈증, 견갑난산, 선천성 기형의 빈도를 비교하였으며, 모성예후로는 양수과다증(>95%), 전자간증, 감염(수술상처, 비뇨기계 감염 등)의 발생빈도를 비교하였다. 결과 : 정상대조군(90명), 내당능 장애군(33명) 및 임신성 당뇨군(36명) 간에 산모의 연령, 산과력, 임신전 BMI에는 차이가 없었으며, 당뇨의 가족력은 정상대조군에 비해 내당능 장애군과 임신성 당뇨군에서 유의하게 높았으나( p<0.001) 이전 임신에서의 임신성 당뇨의 빈도는 차이가 없었다. 신생아예후에서는 과체중아, 거대아, 조기분만, 1분 및 5분 아프가 점수, 견갑난산 및 선천성 기형의 발생은 세 군간에 차이가 없었으나, 신생아의 고빌리루빈혈증은 대조군에 비해 임신성 당뇨군 및 내당능 장애군에서 유의하게 높은 빈도를 보였으며(p=0.032, p<0.001), 신생아중환자실 입원일수는 내당능 장애군에서 대조군보다 유의하게 길었다(p=0.016). 모성 예후에서는 양수과다증, 감염의 빈도는 세 군 사이에 차이가 없었으나, 전자간증의 이환율은 임신성 당뇨군과 내당능장애군이 정상대조군에 비하여 유의하게 높았다(p=0.023, p=0.018). 결론 : 100 g 경구 당내성 검사상 하나의 이상수치를 보이는 내당능 장애 산모에서 거대아의 빈도는 증가하지 않았으나 신생아의 고빌리루빈혈증이 유의하게 증가하였으며 산모에서는 전자간증의 이환율이 증가하였다. Objective : To compare the perinatal outcomes of pregnant women with 100 g oral glucose tolerance test (OGTT) proven impaired glucose tolerance (IGT), with normal control and gestational diabetes mellitus (GDM) groups. Methods : 159 pregnant women who had visited our medical center between March 2002 and March 2004, positive (≥140 g) for 50 g OGTT were included in this study. IGT was defined by the presence of one abnormal 100 g OGTT glucose value, and they were compared with the control group, and the GDM group(with at least 2 abnormal glucose values). The maternal and neonatal outcomes were assessed among three groups. Results : Even though familial history of DM was significantly higher in the IGT and GDM group (p<0.001) compared with the control group, no difference was observed in the frequency of previous GDM. The rate of fetal macrosomi a (>4 kg) and hypoglycemia was significantly increased in GDM group than other groups. The difference in the frequency of i) large for gestational age birthweight (>90 percentile) ii) preterm delivery, iii) APGAR score (1-min and 5-min), iv) shoulder dystocia, and v) congenital anomalies among the three groups was not notable-however, the incidence of neonatal hyperbilirubinemia was significantly higher and duration of NICU admission is significantly longer in the IGT group, compared to the control group (p<0.001). In maternal outcomes, whereas no significant difference was observed concerning the frequency of i) polyhydramnios (>95%) ii) infections (genitourinary and surgical wounds) in the three groups, the prevalence of preeclampsia was significantly higher in the IGT (p=0.018) and GDM group (p=0.023), compared with the control group. Conclusion : Neonatal hyperbilirubinemia, as well as maternal preeclampsia were significantly elevated in the IGT group. The results obtained thus far demonstrate the possibility of the need for active perinatal care with therapeutic intervention in pregnant women with IGT.

자궁내막증에서 혈청 CA 125 및 CA 19-9의 임상적 활용에 관한 연구

이경욱 ( Kyong Wook Yi ),박일해 ( Il Hae Park ),여민구 ( Min Koo Yeo ),송승훈 ( Seung Hun Song ),이재관 ( Jae Kwan Lee ),오민정 ( Min Jung Oh ),서호석 ( Ho Suk Saw ),박용균 ( Yong Kyun Park ),허준용 ( Jun Yong Hur ) 대한산부인과학회 2005 Obstetrics & Gynecology Science Vol.48 No.9

Laparoscopic management of early omental pregnancy detected by MRI: Case report

이경욱 ( Kyong Wook Yi ),( Kyeong A So ),( Kyung Hee Lee ),( Min Jung Oh ),( Jun Young Hur ),( Ho Suk Saw ),( Yang Kyun Park ),( Jae Kwan Lee ) 대한산부인과학회 2007 대한산부인과학회 학술대회 Vol.93 No.-

Drospirenone의 약리학적 특성

이경욱 ( Kyong Wook Yi ),허준용 ( Jun Young Hur ) 대한폐경학회 2008 대한폐경학회지 Vol.14 No.1

In postmenopausal women, hormone therapy (HT) relives the part of postmenopausal symptoms, such as vasomotor symptoms (hot flushes, palpitation), psychological well-being, and osteoporosis. As with estrogens, the various progestogens used in HT for protection of the endometrium may differ as to their pharmacological properties. Drospirenone (DRSP) is an analogue to spironolactone, aldosterone antagonist, and is unique progestogen. The pharmacological profile of DRSP resembles that of the natural progesterone, especially with regard to anti-mineralocorticoid and anti-aldosterone activities. Recent clinical trials have been confirmed that DRSP/estradiol combination provides effective relief of menopausal symptoms, such as hot flushes, genitourinary atropy, and improves bone mineral density; thus reducing the risk of osteoporosis. In addition, the anti-aldosterone activityof DRSP counteracts sodium and water retention contributes to the maintenance of stable body weight, and has potential benefits for blood pressure in postmenopausal women. The DRSP/estradiol combination offers a new choice beyond the effective management of menopausal symptoms, with additional favorable effects due to its anti-aldosterone properties.